Methylene blue as adjunctive therapy in septic shock: correct drug diluent derives optimal efficacy
- PMID: 37644588
- PMCID: PMC10466802
- DOI: 10.1186/s13054-023-04615-2
Methylene blue as adjunctive therapy in septic shock: correct drug diluent derives optimal efficacy
Conflict of interest statement
The authors declare that they have no competing interests.
Comment on
-
Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial.Crit Care. 2023 Mar 13;27(1):110. doi: 10.1186/s13054-023-04397-7. Crit Care. 2023. PMID: 36915146 Free PMC article. Clinical Trial.
References
-
- Ibarra-Estrada M, Kattan E, Aguilera-González P, Sandoval-Plascencia L, Rico-Jauregui U, Gómez-Partida CA, Ortiz-Macías IX, López-Pulgarín JA, Chávez-Peña Q, Mijangos-Méndez JC, Aguirre-Avalos G, Hernández G. Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. Crit Care. 2023;27(1):110. doi: 10.1186/s13054-023-04397-7. - DOI - PMC - PubMed
-
- Methylthioninium chloride 5mg/ml solution for injection. https://www.medicines.org.uk/emc/product/6898/smpc#gref. Last accessed on 24 July 2023.
-
- Safety Wires—Don’t dilute ProvayBlue in normal Saline. ISMP Nurse Advise ERR. Vol 15, Issue 5, 2017.
-
- Australian Product Information - Methylene Blue Injection PI V02. https://www.phebra.com. Last accessed on 24 July 2023.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
